Monitoring and evaluation of efficacy and safety of Artesunate-Amodiaquine (ASAQ) in Ta Sanh Health Centre (Battambong) and Kvav Health Centre (Siem Reap) with a single 15-mg adult dose of Primaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Cambodia

Not Applicable

Completed

• Conditions: Patients with Plasmodium falciparum infection; Infection - Other infectious diseases

• Registration Number: ACTRN12619001628134
• Lead Sponsor: Ministry of Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2017-03-26
• Study Start: 2019-11-25
• Last Update Posted: 10 December 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with the bodyweight of 8 kg or above
- P. falciparum infection
- Ability to swallow the drug
- Ability and willingness to comply with the study protocol

Exclusion Criteria

- Pregnancy or lactation
- Severe malaria
- Mixed malaria infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of treatment successful which was confirmed by the polymerase chain reaction (PCR) based on the fresh blood.[Post-treatment at day 28]

Secondary Outcome Measures

Name	Time	Method
the proportions of the drug-induced adverse events such as vomiting, insomnia, and abdominal pain based on clinical examination, direct observation and participant self-reported [During the treatment at day 0, 1, and 2 and post-treatment at day 3]